EMA cuts new PV teeth on Servier bone drug
This article was originally published in Scrip
The European Medicines Agency's Pharmacovigilance Risk Assessment Committee (PRAC) has called for further restrictions on the use of Servier's osteoporosis drug Protelos/Osseor (strontium ranelate) because it may increase the risk of heart problems. It has recommended in-depth evaluation of the product's risks and benefits, and limiting the product's use while this is carried out. Restrictions were placed on the drug last year when other risks were identified.
You may also be interested in...
BioNTech extends Pfizer partnership to cover COVID-19 vaccine development and distribution while Fosun Pharma takes Chinese rights.
Dietmar Hopp, 80% shareholder of German mRNA company CureVac, has rejected the possibility that the company would sign an exclusive deal with the US for its investigational coronavirus vaccine.
Infographic: Scrip homes in on key figures for companies integrating major acquisitions or divesting significant parts of their business.